FDA requires more time to review Moderna's COVID-19 vaccine for adolescents

Moderna has been told that the US FDA will require additional time to complete the assessment of its COVID-19 vaccine, for use in adolescents between the age group 12 to 17 years.

Highlights

• FDA will require additional time for assessing Moderna’s vaccine
• This vaccine poses a risk of Myocarditis in adolescent males

The FDA informed Moderna that the review will....